Clinical Trials

ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND#122782) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

• Conditions: Sarcoma Rhabdomyosarcoma New Diagnosis, Adult - Sarcoma Rhabdomyosarcoma New Diagnosis

PURPOSE: This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosa ...More